Top Clicks

A new cancer-drug distribution system that aims to cut drug costs for community oncology practices around the country is being launched by OneOncology Inc., of Orlando, Fla., which started its Web-based system

In a challenge to the status quo of the drug-distribution business, OneOncology plans to conduct periodic online “reverse auctions.” Wholesale-drug distributors would bid on the opportunity to fill product orders pooled from hundreds of community oncology clinics around the country. OneOncology thinks this will give smaller clinics access to lower prices than they get now, according to Chief Executive
Steven Kirchof. Under the current system, small practices typically have longstanding relationships with distributors.
“It threatens the existing status quo for companies like Oncology Supply,” said Kirchof, a former executive with International Business Machines Corp.’s ( IBM) healthcare unit. “I believe that most of the distributors will come and play, and probably play very aggressively.”

Like this:

IDENTIGENE Becomes First DNA Testing Lab to Promise Fast Results with a Money-Back Guarantee . The company now Now Offers the Industry’s First Money-Back Guarantee, together with a Three-Day Turnaround on Results

the website says IDENTIGENE is the onlyDNA testing lab with a money-back guarantee

The findings made by Minnie Sarwal, MD, PhD, a pediatric nephrologist at Packard Children’s is a major advantage in organ transplantation treatment. Transplant recipients who share the same pattern of genes but are still on conventional medication may be able to reduce or eliminate their lifelong dependence on immunosuppressive drugs. The study may also help physicians determine how best to induce acceptance, or tolerance, of donor organs in all transplant patients, regardless of their gene expression profiles.

Although the anti-rejection medications, known as immunosuppressants, tamp down the immune system enough to permit lifesaving organ transplants, their benefits come at a price. They also quash the body’s natural response to dangerous invaders, such as bacteria and viruses, and to rogue cancer cells. Transplant physicians prescribing immunosuppressants to their patients walk a fine line between avoiding organ rejection and increasing the risk of infection and cancer

The researchers used microarray, or gene chip, technology to compare gene expression patterns in blood samples from 16 healthy volunteers with those from three groups of adult kidney transplant recipients from the United States, Canada and France

Information technology company Microsoft will give technical assistance to enhance access to online research for scientists, thats when most of the publishers of scientific journals are fighting against Open Access journals. Take a look at the blog on the subject by Greg at nodalpoint

Announced at a meeting in Washington in July Representatives from the World Health Organization, the Food and Agriculture Organization, the UN Environmental Programme, and leading science and technology publishers, together with representatives from Cornell and Yale Universities met to officially extend their free access to peer-reviewed journals for many developing world scientists to 2015, in line with the UN’s Millennium Development Goals.

Microsoft will provide new software called the Intelligent Application Gateway 2007 (formally Whale) that will meet increased demand for access to heavily trafficked portals and perform at the standards of today’s most heavily trafficked websites. The system will also enhance security through authentication of users when they log on.

Well every one is writing about google and its foray into biology and life science, so what is going on with Other companies .

Microsoft started its BioIT alliance During 2006 and guss what Bill Gates said during the launch “Advances in our understanding of the human genome promise to revolutionize medicine and open the door to therapies that are tailored to individuals”, means they have bigger plans. just like google entered 23andME

Founding members of the alliance include Accelrys Software, Affymetrix, Amylin Pharmaceuticals, Applied Biosystems and The Scripps Research Institute, among more than a dozen other life sciences and IT companies.

THe Haifa Lab of IBM provides the Technlogy for Clinicalgenomics and leads the research in lifesciences fieds.

The Clinica, Genomics division plans to provide technology to integrate clinial genomics data and HL7 and other complaince protocls followed in clinical research and clinia, trial and integrate them to provide better and focused clinical trials

Access all major ontologies that provide genotype-phenotype relationships like OMIM, PharmGKB, etc.

Parse the encapsulated raw genomic data and bubble-up selected genomic data items based on ontological knowledge as well as the patient clinical data

Compare two Genotypes (the data model at the heart of the HL7 specs) in order to provide case-based reasoning services to decision support application that will use CGL7 as a specialized clinical genomics middleware

Find a similar pedigree in case base of pedigrees in order to support risk assessment applications that base their assessment on family history

Citrix Acquire XenSource to Enter Server and Desktop Virtualization Markets. So whats it has got to do with genetics and bioinformatics , XenSource is the leading provider of enterprise-class virtual infrastructure solutions Originally created by the founders of XenSource at University of Cambridge, the Xen virtualization “engine” is now developed collaboratively by an active open source community.

Scientists were using a 16-node cluster for bioinformatics especially in case of smithman waterman balast, with each node containing a single-core processor. Three years ago, dual-processor nodes became common, so that same scientist needed an 8-node cluster. And then when dual-core became standard, a 4-nodes cluster could take over. With virtualization you can blow it up to many more nodes with no need for any expensive hardware.